Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O75487
UPID:
GPC4_HUMAN
Alternative names:
K-glypican
Alternative UPACC:
O75487; B2R6J7; B4E2C0; Q6ZMA6; Q96L43; Q9NU08; Q9UJN1; Q9UPD9
Background:
Glypican-4, also known as K-glypican, is a cell surface proteoglycan with heparan sulfate chains. It plays a crucial role in the development of kidney tubules and the central nervous system, suggesting its involvement in cellular signaling and tissue organization.
Therapeutic significance:
Glypican-4's association with Keipert syndrome, a genetic disorder marked by craniofacial, digital abnormalities, and potential cognitive impairment, underscores its clinical importance. Understanding Glypican-4's function could lead to novel therapeutic strategies for managing Keipert syndrome and related conditions.